If At First You Don't Succeed, Trikafta Again.

Autor:	Loyd I; College of Medicine (IL), University of Oklahoma Health Sciences Center, Oklahoma City, OK., Papac N; Department of Dermatology (NP, JH, JL), University of Oklahoma Health Sciences Center, Oklahoma City, OK., Hirshburg J; Department of Dermatology (NP, JH, JL), University of Oklahoma Health Sciences Center, Oklahoma City, OK., Levin J; Department of Dermatology (NP, JH, JL), University of Oklahoma Health Sciences Center, Oklahoma City, OK., Dannelley J; Department of Pediatrics (JD, JD, NM), University of Oklahoma Health Sciences Center, Oklahoma City, OK., Dorris J; Department of Pediatrics (JD, JD, NM), University of Oklahoma Health Sciences Center, Oklahoma City, OK., Stratton J; College of Medicine (IL), University of Oklahoma Health Sciences Center, Oklahoma City, OK.; Department of Dermatology (NP, JH, JL), University of Oklahoma Health Sciences Center, Oklahoma City, OK.; Department of Pediatrics (JD, JD, NM), University of Oklahoma Health Sciences Center, Oklahoma City, OK., Mehdi N; Department of Pediatrics (JD, JD, NM), University of Oklahoma Health Sciences Center, Oklahoma City, OK.
Jazyk:	angličtina
Zdroj:	The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG [J Pediatr Pharmacol Ther] 2022; Vol. 27 (5), pp. 467-469. Date of Electronic Publication: 2022 Jul 06.
DOI:	10.5863/1551-6776-27.5.467
Abstrakt:	Adverse reactions, including severe cutaneous reactions, to cystic fibrosis transmembrane conductance regulator (CFTR) modulators have been described in the literature. Herein we present a drug eruption in response to elexacaftor/tezcaftor/ivacaftor (brand name, Trikafta) in a 7-year-old male with cystic fibrosis, followed by desensitization and successful continuation. A review of the literature outlining similar cases is provided. Attempting to mitigate and manage drug reactions to CFTR modulators is essential because they represent vital and irreplaceable therapies for individuals with cystic fibrosis (CF). Competing Interests: Disclosures. The authors declare no conflicts or financial interest in any product or service mentioned in the manuscript. The authors had full access to all patient information in this report and take responsibility for the integrity and accuracy of the report. (Copyright. Pediatric Pharmacy Association. All rights reserved. For permissions, email: membership@pediatricpharmacy.org 2022.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu